Guanine

Guanine

SCHEMBL4857241

Nc1nc(=O)[nH]cc1F.Nc1nc2[nH]cnc2c(=O)[nH]1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TMP1

The experimentally established mechanism targets of Guanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
GLA P06280 1/20 0.44
PMP22 Q01453 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PNP P00491 4/20 0.39
DYRK1A Q13627 1/20 0.36
NOS1 P29475 1/20 0.34
PARP1 P09874 1/20 0.33
MAPT P10636 1/20 0.33
AKR1B1 P15121 1/20 0.32
MITF O75030 1/20 0.32
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 1/20 0.32
HBB P68871 1/20 0.32
HIF1A Q16665 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanine SCHEMBL4301039 0.84 KDM4E (0.44) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL5259 0.83 ALDH1A1 (0.61) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL4658042 0.83 ALDH1A1 (0.61) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL9512016 0.81 ALDH1A1 (0.59) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL21611717 0.81 ALDH1A1 (0.59) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL4063556 0.81 ALDH1A1 (0.59) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL28240965 0.81 ALDH1A1 (0.59) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL2895087 0.81 ALDH1A1 (0.59) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL865492 0.81 ALDH1A1 (0.59) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL28373862 0.81 ALDH1A1 (0.59) KDM4EALDH1A1LMNAGLAPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439351-B2 2′ or 3′ -deoxy and 2′, 3′-dideoxy-β-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents THE UAB RESEARCH FOUNDATION (US) 2008-10-21 US disclosed
US-20050101776-A1 2' or 3' -deoxy and 2' , 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents GOSSELIN GILLES (FR) 2005-05-12 US disclosed
US-20020120130-A1 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents GOSSELIN GILLES (FR) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101776-A1 2' or 3' -deoxy and 2' , 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents DUT, DCTD, DERA KDM4E 2857/4885ALDH1A1 448/4885LMNA 1101/4885
US-20020120130-A1 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents DUT, DCTD, TYMP KDM4E 2409/4885ALDH1A1 498/4885LMNA 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.